Cargando…

Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine

INTRODUCTION: Onabotulinum toxin A (OnabotA) cyclic treatment is approved for the prophylactic treatment of chronic migraine (CM), a highly disabling disorder. Although treatment response varies among patients, current guidelines suggest to stop treatment after cycle 2 if no response is achieved. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarchielli, Paola, Romoli, Michele, Corbelli, Ilenia, Bernetti, Laura, Verzina, Angela, Brahimi, Elona, Eusebi, Paolo, Caproni, Stefano, Calabresi, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723003/ https://www.ncbi.nlm.nih.gov/pubmed/29255444 http://dx.doi.org/10.3389/fneur.2017.00655

Ejemplares similares

P066. Migraine with aura in the locker room: 4 case reports
por: Bernetti, Laura, et al.
Publicado: (2015)

O064. Antiepileptic drugs in migraine and epilepsy disorders: who is at increased risk of adverse events?
por: Romoli, Michele, et al.
Publicado: (2015)

Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study
por: Corbelli, Ilenia, et al.
Publicado: (2022)

Migraine with aura in the locker room: three case reports
por: Corbelli, Ilenia, et al.
Publicado: (2011)

Migraine-specific quality of life questionnaire and relapse of medication overuse headache
por: Caproni, Stefano, et al.
Publicado: (2015)

Drug-dependence behaviour and outcome of medication-overuse headache after treatment
por: Corbelli, Ilenia, et al.
Publicado: (2012)

Long term headache duration is a factor predicting nonresponse to detoxification and advice in medication overuse headache
por: Caproni, Stefano, et al.
Publicado: (2014)

Migraine and epilepsy: what value today?
por: Costa, Cinzia, et al.
Publicado: (2015)

Dural arteriovenous fistulas and headache features: an observational study
por: Corbelli, Ilenia, et al.
Publicado: (2020)

Immunological findings in patients with migraine and other primary headaches: a narrative review
por: Biscetti, Leonardo, et al.
Publicado: (2021)

Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks
por: Coppola, Gianluca, et al.
Publicado: (2022)

HDAC3 role in medication consumption in medication overuse headache patients: a pilot study
por: Pisanu, Claudia, et al.
Publicado: (2015)

Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations
por: Barbanti, Piero, et al.
Publicado: (2017)

The Role of Onabotulinum Toxin Type A in the Management of Chronic Non-migraine Headaches
por: Jia, Cassie, et al.
Publicado: (2019)

Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms
por: Biscetti, Leonardo, et al.
Publicado: (2021)

Further Evidence that Onabotulinum Toxin is a Viable Treatment Option for Pediatric Chronic Migraine Patients
por: Ali, Sameer S, et al.
Publicado: (2019)

Efficacy of Onabotulinum Toxin A on Obsessive–Compulsive Traits in a Population of Chronic Migraine Patients
por: Viticchi, Giovanna, et al.
Publicado: (2022)

Onabotulinum toxin A vs. incobotulinum toxin A for the treatment of chronic migraine: a retrospective review
por: Lucchese, Scott, et al.
Publicado: (2023)

Cortical spreading depression as a target for anti-migraine agents
por: Costa, Cinzia, et al.
Publicado: (2013)

Biological substrates of migraine
por: Calabresi, Paolo
Publicado: (2015)

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
por: Eusebi, Paolo, et al.
Publicado: (2018)

Voluntary stopping of eating and drinking: is medical support ethically justified?
por: Jox, Ralf J., et al.
Publicado: (2017)

Application of ICHD 2nd edition criteria for primary headaches with the aid of a computerised, structured medical record for the specialist
por: Sarchielli, P., et al.
Publicado: (2005)

Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity
por: Rohrsted, Malene, et al.
Publicado: (2012)

Repeated onabotulinum neurotoxin A injections for drooling in children with neurodisability
por: Bekkers, Stijn, et al.
Publicado: (2021)

Patients profiling for Botox® (onabotulinum toxin A) treatment for migraine: a look at white matter lesions in the MRI as a potential marker
por: Bumb, Anja, et al.
Publicado: (2013)

Is an “Epigenetic Diet” for Migraines Justified? The Case of Folate and DNA Methylation
por: Fila, Michal, et al.
Publicado: (2019)

Levodopa in Parkinson’s Disease: Current Status and Future Developments
por: Tambasco, Nicola, et al.
Publicado: (2018)

Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study
por: García-Azorín, David, et al.
Publicado: (2022)

Evaluation of the effect of 100U of Onabotulinum toxin A on detrusor contractility in women with idiopathic OAB: A multicentre prospective study
por: De Rienzo, Gaetano, et al.
Publicado: (2021)

Platelets in migraine
por: Sarchielli, Paola, et al.
Publicado: (2001)

Pathophysiological Bases of Comorbidity in Migraine
por: Altamura, Claudia, et al.
Publicado: (2021)

The sense of stopping migraine prophylaxis
por: Al-Hassany, Linda, et al.
Publicado: (2023)

Current and emerging evidence-based treatment options in chronic migraine: a narrative review
por: Agostoni, Elio Clemente, et al.
Publicado: (2019)

Trigger factors of migraine and tension-type headache
por: Sarchielli, P.
Publicado: (2006)

Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation
por: Trinh, Hamilton, et al.
Publicado: (2019)

What’s new in the treatment of acute migraine
por: Gallai†, Virgilio, et al.
Publicado: (2004)

EHMTI-0278. Onabotulinum toxin a for hemicrania continua: a case series of 8 patients
por: Miller, S, et al.
Publicado: (2014)

Onabotulinum toxin-A (Botox) for spastic equinus in cerebral palsy: a prospective kinematic study
por: Hastings-Ison, T., et al.
Publicado: (2018)

New Injection Points of Onabotulinum Toxin A for Spastic Paralysis of the Fingers: Eight Cases of Report
por: Yamada, Shoko Merrit, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_blck3lr89b5stshmkg23dcpksh